Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33,860 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial.
Song Y, Zhou H, Zhang H, Liu W, Shuang Y, Zhou K, Lv F, Xu H, Zhou J, Li W, Wang H, Zhang H, Huang H, Zhang Q, Xu W, Ge Z, Xiang Y, Wang S, Gao D, Yang S, Lin J, Wang L, Zou L, Zheng M, Liu J, Shao Z, Pang Y, Xia R, Chen Z, Hou M, Yao H, Feng R, Cai Z, Zhang M, Ran W, Liu L, Zeng S, Yang W, Liu P, Liang A, Zuo X, Zou Q, Ma J, Sang W, Guo Y, Zhang W, Cao Y, Li Y, Feng J, Du X, Zhang X, Zhao H, Zhou H, Yu J, Sun X, Zhu J, Qiu L. Song Y, et al. Among authors: yang s, yang w. Adv Ther. 2021 Apr;38(4):1889-1903. doi: 10.1007/s12325-020-01603-8. Epub 2021 Mar 9. Adv Ther. 2021. PMID: 33751401 Clinical Trial.
A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta® in healthy Chinese male subjects.
Liu G, Xu Z, Yang W, Xue J, Wang Y, Liu Z, Cui Y, Qu X, Chang T, Yu S, Cheng Y, Zhou Y, Chen J, Ren Q, Wang W, Deng Q, Wang Z, Yang H. Liu G, et al. Among authors: yang w, yang h. Expert Opin Biol Ther. 2022 Feb;22(2):187-195. doi: 10.1080/14712598.2021.1988567. Epub 2021 Oct 18. Expert Opin Biol Ther. 2022. PMID: 34607519 Clinical Trial.
A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects.
Liu Z, Gao Z, Yang W, Zhang L, Xiao N, Qu D, Su Z, Xu K, Liu G, Wang Y, Ren Q, Yu S, Cheng Y, Zhou Y, Deng Q, Zhao Y, Wang Z, Yang H. Liu Z, et al. Among authors: yang w, yang h. Expert Opin Drug Metab Toxicol. 2022 Jul-Aug;18(7-8):519-527. doi: 10.1080/17425255.2022.2113382. Epub 2022 Aug 18. Expert Opin Drug Metab Toxicol. 2022. PMID: 35961948 Clinical Trial.
Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenström's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study.
Cao XX, Jin J, Fu CC, Yi SH, Zhao WL, Sun ZM, Yang W, Li DJ, Cui GH, Hu JD, Liu T, Song YP, Xu B, Zhu ZM, Xu W, Zhang MZ, Tian YM, Zhang B, Zhao RB, Zhou DB. Cao XX, et al. Among authors: yang w. EClinicalMedicine. 2022 Oct 4;52:101682. doi: 10.1016/j.eclinm.2022.101682. eCollection 2022 Oct. EClinicalMedicine. 2022. PMID: 36313145 Free PMC article.
Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial.
Zhou H, Wang Y, Chen J, He A, Jin J, Lu Q, Zhao Y, Li J, Hou M, Su L, Lai X, Wang W, Liu L, Ma Y, Gao D, Lai W, Zhou X, Jing H, Zhang J, Yang W, Ran X, Lin C, Hao J, Xiao T, Huang Z, Zhu Z, Wang Q, Fang B, Wang B, Song Y, Cai Z, Liu B, Zhu Y, Yang X, Kang X, Li J, Chen W. Zhou H, et al. Among authors: yang w, yang x. Ann Hematol. 2024 Mar;103(3):855-868. doi: 10.1007/s00277-023-05558-y. Epub 2023 Dec 19. Ann Hematol. 2024. PMID: 38112795 Free PMC article.
Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial.
Lin N, Sun X, Zhou H, Zou L, Zhou K, Liu L, Yang H, Hu K, Cai Q, Liu Y, Jin J, Zhang L, Li W, Guo Y, Yang W, Luo F, Wang Z, Zhu R, Yang L, Song D, Song Y, Zhu J. Lin N, et al. Among authors: yang l, yang w, yang h. Haematologica. 2024 Sep 5. doi: 10.3324/haematol.2024.284973. Online ahead of print. Haematologica. 2024. PMID: 39234866 Free article.
33,860 results
You have reached the last available page of results. Please see the User Guide for more information.